Intravitreal triamcinolone versus intravitreal bevacizumab for diabetic macular edema: A meta-analysis

International Journal of Ophthalmology

Volumn 6, Issue 4, 2013, Pages 546-552

  Zhang, Xiao Ling ^a   Chen, Jian ^a   Zhang, Ri Jia ^a   Wang, Wen Jie ^a   Zhou, Qing ^a   Qin, Xiao Yan ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Bevacizumab; Diabetic macular edema; Meta analysis; Triamcinolone

Indexed keywords

EID: 84894545906     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.04.26     Document Type: Article

References (43)

1. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye. 2010;24(11):1692-1699.
2. Habib SL, Rojna M. Diabetes and risk of cancer. ISRN Oncol. 2013;2013:583786.
3. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The wisconsin epidemiologic study of diabetic retinopathy. XV. The longterm incidence of macular edema. Ophthalmology. 1995;102(1):7-16.
4. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The wisconsin epidemiologic study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497-503.
5. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(7):915-930.
6. Kumar B, Gupta SK, Saxena R, Srivastava S. Current trends in the pharmacotherapy of diabetic retinopathy. J Postgrad Med. 2012;58(2):132-139.
7. Wang H, Sun X, Liu K, Xu X. Intravitreal Ranibizumab (Lucentis) for the Treatment of Diabetic Macular Edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res. 2012;37(8):661-670.
8. Liu L, Wu X, Geng J, Yuan Z, Chen L. IVTA as adjunctive treatment to PRP and MPC for PDR and macular edema: a metaanalysis. Plos One. 2012;7(9):e44683.
9. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116(6):1142- 1150.
10. Lam DS, Lai TY, Lee VY, Chan CK, Liu DT, Mohamed S, Li CL. Efficacy of 1.25mg versus 2.5mg intravitreal bevacizumab for diabetic macular edema six-month results of a randomized controlled trial. Retina. 2009;29(3):292-299.
11. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-1867.
12. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin P G. A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema 24-Month Data: Report 3. Arch Ophthalmol. 2012;130(8):972-979.
13. Yilmaz T, Cordero-Coma M, Gallagher MJ, Teasley LA. Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema. Acta Ophthalmol. 2011;89(8):709-717.
14. Goyal S, La Valley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2011;249(1):15-27.
15. Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: Three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004;111(11):2044-2049.
16. Karacorlu M, Ozdemir H, Karacorlu S, Alacali N, Mudun B, Burumcek E. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye. 2005;19(4):382-386.
17. Negi AK, Vernon S, Lim CS, Owen-Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye. 2005;19(7):747-751.
18. Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, Lavaque AJ, Larson RJ. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009;116(5):902-911; quiz 912-913.
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
20. Sobaci G, Ozge G, Erdurman C, Durukan HA, Bayraktar ZM. Comparison of grid laser, intravitreal triamcinolone, and intravitreal bevacizumab in the treatment of diffuse diabetic macular edema. Ophthalmologica. 2012;227(2):95-99.
21. Azad R, Sain S, Sharma Y R, Mahajan D. Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study. Oman J Ophthalmol. 2012;5(3):166-170.
22. Penha FM, Maia M, Cardillo JA, Arevalo JF, Wu L, Rodriguez FJ, Berrocal MH, Farah ME. Pan-American Collaborative Retina Study. Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema. Acta Ophthalmol. 2012;90(2):e160-161.
23. Kreutzer TC, Al Saeidi R, Kook D, Wolf A, Ulbig MW, Neubauer AS, Haritoglou C. Comparison of intravitreal bevacizumab versus triamcinolone f or the treatment of diffuse diabetic macular edema. Ophthalmologica. 2010;224(4):258-264.
24. Zhou Y Y, Zhang RJ. Avastin combined with vitreous cavity injection of triamcinolone acetonide in treatment of diabetic retinopathy with macular edema. Int J Ophthalmol. 2010;10(3):475-476.
25. Chakrabarti M, John SR, Chakrabarti A. Intravitreal monotherapy with bevacizumab (IVB) and triamcinolone acetonide (IVTA) versus combination therapy (IVB and IVTA) for recalcitrant diabetic macular edema. Kerala Journal of Ophthalmology. 2009;21(2):139-148.
26. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008;145(5):854-861.
27. Isaac DL, Abud MB, Frantz KA, Rassi AR, Avila M. Comparing intravitreal triamcinolone acetonide and bevacizumab injections f or the treatment of diabetic macular oedema: a randomized double-blind study. Acta Ophthalmol. 2012;90(1):56-60.
28. Lim JW, Lee HK, Shin MC. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica. 2012;227(2):100-106.
29. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab f or treatment of refractory diabetic macular oedema (IBEME study) Br J Ophthalmol. 2008;92(1):76-80.
30. Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol. 2011;5:1011-1016.
31. Shahin MM, El-Lakkany RS. A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema. Middle East Afr J Ophthalmol. 2010;17(3):250-253.
32. Rensch F, Spandau UH, Wickenhauser A, Jonas JB. Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide. Acta Ophthalmol. 2010;88(2):e36-37.
33. Larsson J, Zhu MD, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol. 2005;139(5):802-806.
34. Browning DJ, Glassman AR, Aiello LP, Beck RW, Brown DM, Fong DS, Bressler NM, Danis RP, Kinyoun JL, Nguyen QD, Bhavsar AR, Gottlieb J, Pieramici DJ, Rauser ME, Apte RS, Lim JI, Miskala PH. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114(3):525-536.
35. Jonas JB, Martus P, Degenring RF, Kreissig I, Akkoyun I. Predictive factors f or visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol. 2005;123(10):1338-1343.
36. Qi HP, Bi S, Wei SQ, Cui H, Zhao JB. Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis. Curr Eye Res. 2012;37(12):1136-1147.
37. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115(10):1750-1755, 1755 e1751.
38. Elman MJ, Bressler N M, Qin HJ, Beck RW, Ferris FL, 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2011;118(4):609-614.
39. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078-1086.
40. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS, RISE and RIDE Research Group Ranibizumab for diabetic macular edema results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
41. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A, RESTORE study group The RESTORE study ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
42. Do DV, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Ruckert R, Sandbrink R, Stein D, Yang K, Beckmann K, Heier JS. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819-1826.
43. Do DV, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658-1665.